UroToday

Association between Neurogenic Bladder Symptom Score and Disability Status in Multiple Sclerosis Patients - Beyond the Abstract

Lower urinary tract symptoms (LUTS) remain one of the most prevalent and disabling clinical manifestations in multiple sclerosis (MS) patients, often emerging early in the disease course and ...
UroToday

CORE-008: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Phase 3 Trial Results for Intravesical Cretostimogene Grenadenorepvec in Bladder Cancer - Mark Tyson CORE-008 Trial Cohort CX: Combining Cretostimogene Grenadenorepvec and Gemcitabine for Bladder ...
UroToday

PIVOT-006: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Phase 3 Trial Results for Intravesical Cretostimogene Grenadenorepvec in Bladder Cancer - Mark Tyson PIVOT-006 Trial: Cretostimogene Grenadenorepvec for Intermediate-Risk Non-Muscle Invasive Bladder ...
UroToday

Regulatory Considerations in the BCG-Naïve Non-Muscle-Invasive Bladder Cancer Setting

(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), ...
UroToday

AUA 2020: Phase 3 Results Of Vicinium In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), ...